Read by QxMD icon Read

Journal of Psychopharmacology

Joseph M Trombello, Michael O Killian, Bruce D Grannemann, Augustus John Rush, Taryn L Mayes, Ramin V Parsey, Melvin McInnis, Manish K Jha, Aasia Ali, Patrick J McGrath, Phil Adams, Maria A Oquendo, Myrna M Weissman, Thomas J Carmody, Madhukar H Trivedi
BACKGROUND/AIMS: While substantial prior research has evaluated the psychometric properties of the 12-item Concise Health Risk Tracking-Self Report (CHRT-SR12 ), a measure of suicide propensity and suicidal thoughts, no prior research has investigated its factor structure, sensitivity to change over time, and other psychometric properties in a placebo-controlled trial of antidepressant medication, nor determined whether symptoms change throughout treatment. METHODS: Participants in the multi-site Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study ( n=278) provided data to evaluate the factor structure and sensitivity to change over time of the CHRT-SR12 through eight weeks of a clinical trial in which participants received either placebo or antidepressant medication (sertraline)...
January 17, 2019: Journal of Psychopharmacology
Katarzyna M Targowska-Duda, Barbara Budzynska, Agnieszka Michalak, Krzysztof Jozwiak, Grazyna Biala, Hugo R Arias
BACKGROUND: Several lines of investigations support the idea that nicotinic acetylcholine receptors modulate neuronal pathways involved in anxiety and depression. AIMS: The purpose of this study was to determine whether 3-furan-2-yl-N-p-tolyl-acrylamide, a highly selective positive allosteric modulator of α7 nicotinic acetylcholine receptors, influences anxiety-like behaviour in mice, and to determine the modulatory activity of 3-furan-2-yl-N-p-tolyl-acrylamide on mice pretreated with either nicotine or selective α7-agonists (i...
January 15, 2019: Journal of Psychopharmacology
Luisa Alessandra Atehortua-Martinez, Cyriaque Masniere, Patrizia Campolongo, Stéphanie Chasseigneaux, Jacques Callebert, Clemens Zwergel, Antonello Mai, Jean-Louis Laplanche, Huixiong Chen, Mélanie Etheve-Quelquejeu, Bruno Mégarbane, Nadia Benturquia
BACKGROUND: The substantial increase in use of 3,4-methylenedioxypyrovalerone (MDPV), a popular recreational synthetic cathinone, has raised legitimate questions about its behavioral consequences and abuse liability. AIMS: The aim of this study was to study MDPV-induced neurobehavioral effects in the rat, using different paradigms traditionally developed to study drug-attributed addictive properties. METHODS: Different patterns of intraperitoneal 3 mg/kg MDPV administration were investigated...
January 15, 2019: Journal of Psychopharmacology
Raquel Vicario-Feliciano, Rebekah L Wigton, Thomas P White, Sukhi S Shergill, Bruno B Averbeck
BACKGROUND: Information sampling is the cognitive process of accumulating information before committing to a decision. Patients across numerous disorders show decreased information sampling relative to controls. AIMS: Here, we used the Beads and the Best Choice Tasks to study the role of dopamine signaling in information sampling. METHODS: Participants were given placebo, amisulpride, or ropinirole in each session, in a double-blind cross-over design...
January 15, 2019: Journal of Psychopharmacology
Małgorzata Frankowska, Joanna Miszkiel, Lucyna Pomierny-Chamioło, Bartosz Pomierny, Giuseppe Giannotti, Agata Suder, Małgorzata Filip
BACKGROUND: Environmental conditions have an important function in substance use disorder, increasing or decreasing the risks of relapse. Several studies strongly support the role of the dopamine D2 -like and metabotropic glutamate type 5 receptors in maladaptive neurobiological responses to cocaine reward and relapse. AIMS: The present study employed cocaine self-administration with yoked-triad procedure in rats to explore whether drug abstinence in different housing conditions affects the drug-seeking behaviour and the dopamine D2 -like and metabotropic glutamate type 5 receptor density and affinity in several regions of the animal brain...
January 15, 2019: Journal of Psychopharmacology
Sander Brooks, Gabriël E Jacobs, Peter de Boer, Justine M Kent, Luc Van Nueten, Guido van Amerongen, Rob Zuiker, Iva Kezic, Remy Luthringer, Peter van der Ark, Joop Ma van Gerven, Wayne Drevets
BACKGROUND: Insomnia is common in patients with major depressive disorder. Although antidepressants improve mood, insomnia often persists as a result of physiological hyperarousal. The orexin-2 receptor is increasingly being recognized as a new target for the treatment of persistent insomnia in major depressive disorder . AIM: This exploratory study investigated the effects of seltorexant on objective sleep parameters and subjective depressive symptoms in antidepressant treated major depressive disorder patients with persistent insomnia...
January 15, 2019: Journal of Psychopharmacology
Jad Kesserwani, Giouliana Kadra, Johnny Downs, Hitesh Shetty, James H MacCabe, David Taylor, Robert Stewart, Chin-Kuo Chang, Richard D Hayes
BACKGROUND: Insight into the effect of clozapine is limited by a lack of controlling for confounding variables in current research. Our objective was to investigate the association between clozapine prescribed at discharge, following an inpatient episode, and risk of readmission into secondary mental health services in patients with schizophrenia and schizoaffective disorder, controlling extensively for confounding variables. METHODS: Clinical records from 3651 patients were analysed in a retrospective observational cohort study...
January 8, 2019: Journal of Psychopharmacology
Paula Sm Yamashita, Daiane S Rosa, Christopher A Lowry, Helio Zangrossi
BACKGROUND: Serotonin plays an important role in the regulation of anxiety, acting through complex modulatory mechanisms within distinct brain structures. Serotonin can act through complex negative feedback mechanisms controlling the neuronal activity of serotonergic circuits and downstream physiologic and behavioral responses. Administration of serotonin or the serotonin 1A receptor agonist, (±)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), into the prefrontal cortex, inhibits anxiety-like responses...
December 19, 2018: Journal of Psychopharmacology
Carol Paton, Clive E Adams, Stephen Dye, Elizabeth Fagan, Chike Okocha, Thomas Re Barnes
BACKGROUND: A quality improvement programme addressing prescribing practice for acutely disturbed behaviour was initiated by the Prescribing Observatory for Mental Health. METHOD: This study analysed data from a baseline clinical audit conducted in inpatient mental health services in member trusts. RESULTS: Fifty-eight mental health services submitted data on 2172 episodes of acutely disturbed behaviour. A benzodiazepine alone was administered in 60% of the 1091 episodes where oral medication only was used and in 39% of the 1081 episodes where parenteral medication (rapid tranquillisation) was used...
December 19, 2018: Journal of Psychopharmacology
Bernard R Bukala, Michael Browning, Philip J Cowen, Catherine J Harmer, Susannah E Murphy
There has been increasing interest in the antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine. Here we assess, for the first time, whether a transdermal scopolamine patch is sufficient to induce changes in cognition that are consistent with the reported cognitive and antidepressant effects of scopolamine. A scopolamine or placebo patch was administered to healthy volunteers ( n=33) for 17 h in a double-blind, between-subject procedure. There was no clear effect of scopolamine patch on emotional cognition, verbal or working memory, suggesting that the effective dose of scopolamine available through the patch is too low to represent a viable antidepressant mechanism...
December 11, 2018: Journal of Psychopharmacology
Llewellyn Mills, Robert A Boakes, Ben Colagiuri
BACKGROUND: Negative expectancies can exacerbate withdrawal symptoms via the nocebo effect. As such, information provided about dose reductions during attempts to taper a drug could contribute to withdrawal symptoms and increase the likelihood of relapse. The current study tested whether blinding participants to dose reductions during a supervised caffeine dose taper reduced these nocebo-induced withdrawal symptoms. METHODS: Three groups of moderate to heavy coffee drinkers had their dose of caffeine reduced (tapered) from 300 mg per day to 0 mg over the course of five days and reported withdrawal symptoms twice daily...
December 11, 2018: Journal of Psychopharmacology
Mohammad-Hadi Farahzadi, Ehsan Moazen-Zadeh, Emran Razaghi, Mohammad-Reza Zarrindast, Reza Bidaki, Shahin Akhondzadeh
BACKGROUND: Riluzole is a glutamate regulator and effective in treatment of neuropsychiatric conditions. AIMS: We assessed riluzole for treatment of methamphetamine dependence. METHODS: In this randomized, double-blind, placebo-controlled clinical trial, male outpatients with methamphetamine dependence who were 18-65 years old received either 50 mg riluzole ( n=34) or placebo ( n=54) twice daily for 12 weeks. Patients were excluded in case of comorbid serious medical conditions or neurologic disorders, comorbid psychiatric disorders other than methamphetamine dependence requiring specific treatment interventions, simultaneous positive urine test result for substances of abuse other than methamphetamine, smoking >3 days per week, simultaneous consumption of medications which are contraindicated or have interaction with riluzole...
December 11, 2018: Journal of Psychopharmacology
Agnieszka Potasiewicz, Joanna Golebiowska, Piotr Popik, Agnieszka Nikiforuk
BACKGROUND: Varenicline, a partial agonist of the α4β2 nicotinic acetylcholine receptor (α4β2-nAChR), is currently used to facilitate smoking cessation. Preclinical and clinical studies have suggested that this compound may also be effective in treating cognitive impairments in schizophrenia. However, it is unclear which nicotinic acetylcholine receptor subtypes may be involved because varenicline is not only a partial agonist for α4β2-nAChRs but also a full agonist for α7 nicotinic acetylcholine receptors (α7-nAChRs)...
December 3, 2018: Journal of Psychopharmacology
Jaclyn N Highland, Patrick J Morris, Panos Zanos, Jacqueline Lovett, Soumita Ghosh, Amy Q Wang, Carlos A Zarate, Craig J Thomas, Ruin Moaddel, Todd D Gould
BACKGROUND: ( R,S)-ketamine has gained attention for its rapid-acting antidepressant actions in patients with treatment-resistant depression. However, widespread use of ketamine is limited by its side effects, abuse potential, and poor oral bioavailability. The ketamine metabolite, ( 2R,6R)-hydroxynorketamine, exerts rapid antidepressant effects, without ketamine's adverse effects and abuse potential, in rodents. METHODS: We evaluated the oral bioavailability of ( 2R,6R)-hydroxynorketamine in three species (mice, rats, and dogs) and also evaluated five candidate prodrug modifications for their capacity to enhance the oral bioavailability of ( 2R,6R)-hydroxynorketamine in mice...
November 29, 2018: Journal of Psychopharmacology
Dominik Groos, Fang Zheng, Manfred Rauh, Benedikt Quinger, Johannes Kornhuber, Christian P Müller, Christian Alzheimer
BACKGROUND: Antipsychotic drugs (APDs) are the mainstay of the pharmacological treatment of psychotic disorders like schizophrenia. While the clinical efficacy of APDs has long since been established, the neurobiological mechanisms underlying their therapeutic benefits are still not well understood. METHODS: Here, we used an escalating amphetamine regimen to induce a psychosis-like state in mice. To achieve clinically relevant drug concentrations in amphetamine-pretreated mice, the typical APD haloperidol or the atypical APD olanzapine were chronically administered via subcutaneously implanted osmotic mini-pumps...
November 29, 2018: Journal of Psychopharmacology
Bettadapura N Srikumar, Pattipati S Naidu, Narasimharaju Kalidindi, Mahesh Paschapur, Bharath Adepu, Siva Subramani, Jignesh Nagar, Ratika Srivastava, Muppana V Sreedhara, Durga Shiva Prasad, Manish Lal Das, Justin V Louis, Vijaya K Kuchibhotla, Shailesh Dudhgaonkar, Rick L Pieschl, Yu-Wen Li, Linda J Bristow, Manjunath Ramarao, Reeba K Vikramadithyan
BACKGROUND: A significant proportion of patients suffering from major depression fail to remit following treatment and develop treatment-resistant depression. Developing novel treatments requires animal models with good predictive validity. MRL/lpr mice, an established model of systemic lupus erythematosus, show depression-like behavior. AIMS: We evaluated responses to classical antidepressants, and associated immunological and biochemical changes in MRL/lpr mice...
November 28, 2018: Journal of Psychopharmacology
Matthew B Warren, Philip J Cowen, Catherine J Harmer
BACKGROUND: The neurocognitive model of antidepressant treatment in depression states that antidepressants work by producing relatively immediate positive shifts in emotional processing, which translate into clinical improvement with time. St John's Wort has shown antidepressant potential in randomised controlled trials; however, its pharmacological actions are broad and it is unknown whether treatment also produces changes in emotional processing. AIMS: We investigated whether short-term treatment with St John's wort has similar effects on emotional processing to those reported with other antidepressants such as selective serotonergic reuptake inhibitors...
November 28, 2018: Journal of Psychopharmacology
Rubén García-Cabrerizo, M Julia García-Fuster
BACKGROUND: The goal of the present study was to utilize the adolescent drug experience as an emerging vulnerability factor for developing psychiatric comorbidities in adulthood that could, in turn, help to elucidate and/or hypothesize possible mechanisms contributing to higher relapse rates. OUTCOMES: The current results showed that adolescent cocaine exposure (15 mg/kg, intraperitoneally, seven days) during early-mid adolescence (postnatal days 33-39) enhanced negative affect in adulthood, by increasing behavioral despair following drug re-exposure and by increasing anhedonia...
November 28, 2018: Journal of Psychopharmacology
Tracey A Larson, Casey E O'Neill, Michaela P Palumbo, Ryan K Bachtell
BACKGROUND: Caffeine consumption by children and adolescents has risen dramatically in recent years, yet the lasting effects of caffeine consumption during adolescence remain poorly understood. AIM: These experiments explore the effects of adolescent caffeine consumption on cocaine self-administration and seeking using a rodent model. METHODS: Sprague-Dawley rats consumed caffeine for 28 days during the adolescent period. Following the caffeine consumption period, the caffeine solution was replaced with water for the remainder of the experiment...
November 28, 2018: Journal of Psychopharmacology
Can-Ming Wang, Zhi-Hang Lin, Zhi-Qiang Lin, Qing-Yang Yao, Yi-Fan Zhang
BACKGROUND AND AIM: Developing fast-acting antidepressants attracts considerable attention. Anemoside A3, a natural triterpenoid glycoside isolated from Pulsatillae Radix, has been reported to produce antidepressant-like action in the forced swim test. We herein explore the fast-onset antidepressant-like potentials and antidepressant mechanisms of anemoside A3. METHODS: The forced swim test and tail suspension test were used to determine the acute antidepressant-like action of anemoside A3...
November 28, 2018: Journal of Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"